Show simple item record

dc.contributor.authorSflomos, G
dc.contributor.authorSchipper, K
dc.contributor.authorKoorman, T
dc.contributor.authorFitzpatrick, A
dc.contributor.authorOesterreich, S
dc.contributor.authorLee, AV
dc.contributor.authorJonkers, J
dc.contributor.authorBrunton, VG
dc.contributor.authorChristgen, M
dc.contributor.authorIsacke, C
dc.contributor.authorDerksen, PWB
dc.contributor.authorBrisken, C
dc.coverage.spatialSwitzerland
dc.date.accessioned2021-11-30T10:36:51Z
dc.date.available2021-11-30T10:36:51Z
dc.date.issued2021-10-27
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/34771558en_US
dc.identifiercancers13215396en_US
dc.identifier.citationCancers (Basel), 2021, 13 (21)
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4904
dc.identifier.doi10.3390/cancers13215396
dc.description.abstractInvasive lobular carcinoma (ILC) accounts for up to 15% of all breast cancer (BC) cases and responds well to endocrine treatment when estrogen receptor α-positive (ER+) yet differs in many biological aspects from other ER+ BC subtypes. Up to 30% of patients with ILC will develop late-onset metastatic disease up to ten years after initial tumor diagnosis and may experience failure of systemic therapy. Unfortunately, preclinical models to study ILC progression and predict the efficacy of novel therapeutics are scarce. Here, we review the current advances in ILC modeling, including cell lines and organotypic models, genetically engineered mouse models, and patient-derived xenografts. We also underscore four critical challenges that can be addressed using ILC models: drug resistance, lobular tumor microenvironment, tumor dormancy, and metastasis. Finally, we highlight the advantages of shared experimental ILC resources and provide essential considerations from the perspective of the European Lobular Breast Cancer Consortium (ELBCC), which is devoted to better understanding and translating the molecular cues that underpin ILC to clinical diagnosis and intervention. This review will guide investigators who are considering the implementation of ILC models in their research programs.en_US
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectELBCCen_US
dc.subjectGEMMen_US
dc.subjectPDXen_US
dc.subjectanimal modelsen_US
dc.subjectcell linesen_US
dc.subjectexperimental modelsen_US
dc.subjectinvasive lobular breast carcinomaen_US
dc.subjectmetastasisen_US
dc.subjecttranslational researchen_US
dc.subjecttumor organoidsen_US
dc.titleAtlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.
dc.typeJournal Article
dcterms.dateAccepted2021-10-21
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/cancers13215396
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-10-27
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancers (Basel)en_US
pubs.issue21
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine control mechanisms
pubs.publication-statusPublished online
pubs.volume13en_US
pubs.embargo.termsNot known
icr.researchteamEndocrine control mechanisms
dc.contributor.icrauthorBrisken, Cathrinen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0